EVEREST STUDY

垂直波分 血管抑制剂 医学 眼科 黄斑变性 吲哚青绿 随机对照试验 视力 外科 贝伐单抗 脉络膜新生血管 化疗
作者
Adrian Koh,Won Ki Lee,Lee-Jen Chen,Shih‐Jen Chen,Yehia Hashad,Hakyoung Kim,Timothy Y. Y. Lai,Stefan Pilz,Paisan Ruamviboonsuk,Erika Tokaji,Annemarie Weisberger,Tock Han Lim
出处
期刊:Retina-the Journal of Retinal and Vitreous Diseases [Lippincott Williams & Wilkins]
卷期号:32 (8): 1453-1464 被引量:576
标识
DOI:10.1097/iae.0b013e31824f91e8
摘要

In Brief Purpose: To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Methods: In this multicenter, double-masked, primarily indocyanine green angiography–guided trial, 61 Asian patients were randomized to verteporfin PDT (standard fluence), ranibizumab 0.5 mg, or the combination. Patients were administered with verteporfin PDT/placebo and initiated with three consecutive monthly ranibizumab/sham injections starting Day 1, and re-treated (Months 3–5) as per predefined criteria. The primary endpoint was the proportion of patients with indocyanine green angiography–assessed complete regression of polyps at Month 6. Secondary endpoints included mean change in best-corrected visual acuity at Month 6 and safety. Results: At Month 6, verteporfin combined with ranibizumab or alone was superior to ranibizumab monotherapy in achieving complete polyp regression (77.8% and 71.4% vs. 28.6%; P < 0.01); mean change ± standard deviation in best-corrected visual acuity (letters) was 10.9 ± 10.9 (verteporfin PDT + ranibizumab), 7.5 ± 10.6 (verteporfin PDT), and 9.2 ± 12.4 (ranibizumab). There were no new safety findings with either drug used alone or in combination. Conclusion: Verteporfin PDT combined with ranibizumab 0.5 mg or alone was superior to ranibizumab monotherapy in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular polypoidal choroidal vasculopathy. All treatments were well tolerated over 6 months. EVEREST, the first, multicenter, double-masked, primarily indocyanine green angiography–guided randomized controlled trial for symptomatic macular polypoidal choroidal vasculopathy, demonstrated superiority of verteporfin photodynamic therapy combined with ranibizumab or alone over ranibizumab monotherapy in achieving complete regression of polyps at Month 6. Best-corrected visual acuity improved in all treatment arms.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mymy发布了新的文献求助10
1秒前
1秒前
经十路以东的应助被侯侯采纳,获得10
2秒前
坚强灵竹完成签到,获得积分20
3秒前
nature大牛发布了新的文献求助10
4秒前
JamesPei的应助被桃汁采纳,获得10
4秒前
勒71发布了新的文献求助10
4秒前
5秒前
你好关注了科研通微信公众号
6秒前
7秒前
7秒前
研友_VZG7GZ的应助被勤劳的瑀采纳,获得10
7秒前
经十路以东的应助被冷艳的胜采纳,获得10
7秒前
所所的应助被健壮小馒头采纳,获得10
8秒前
8秒前
顾矜的应助被sjyu1985采纳,获得100
8秒前
9秒前
橘子汽水完成签到 ,获得积分10
9秒前
经十路以东的应助被yeeee采纳,获得10
9秒前
10秒前
lolimay完成签到,获得积分10
11秒前
11秒前
11秒前
12秒前
二三发布了新的文献求助10
12秒前
不会化学完成签到,获得积分10
12秒前
一木发布了新的文献求助10
14秒前
14秒前
酷波er的应助被美酶桑内采纳,获得10
15秒前
wanci的应助被凪凪采纳,获得10
15秒前
123william发布了新的文献求助10
15秒前
qiangqiangqiang完成签到 ,获得积分10
15秒前
16秒前
鹭江发布了新的文献求助10
17秒前
18秒前
焦一诺发布了新的文献求助10
18秒前
MMP发布了新的文献求助30
18秒前
万能图书馆的应助被Echo采纳,获得40
18秒前
Hong713完成签到,获得积分10
18秒前
脑洞疼的应助被Echo采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193925
求助须知:如何正确求助?哪些是违规求助? 9579945
关于积分的说明 21868504
捐赠科研通 7793568
什么是DOI,文献DOI怎么找? 3437462
关于科研通互助平台的介绍 2560923
邀请新用户注册赠送积分活动 2484250